trial
as of 2026-07-01Safety and Efficacy of Cariprazine in Patients With Schizophrenia
NCTId NCT01104766
at a glance
Phase 3 · Completed
Enrollment 617 (actual)
Sponsored by Forest Laboratories
Primary completion 2011-12-20
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 3
Status
Completed
Enrollment
617 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2010-04-23
Primary completion
2011-12-20
Eligibility
ALL · 18 Years · 60 Years
Interventions & indications
Sponsors
Forest LaboratoriesLead Sponsor
Gedeon Richter Ltd.Collaborator
Investigators
1
Raffaele Migliore, MAStudy Director
Sites
58 total
Little Rock, United StatesSpringdale, United StatesEscondido, United StatesOceanside, United StatesRiverside, United StatesSan Diego, United StatesTorrance, United StatesLittleton, United StatesWashington D.C., United StatesBradenton, United StatesHonolulu, United StatesChicago, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
617
Phase
PHASE3
Primary Completion Date
2011-12-20
Status
COMPLETED
relationships
The graph out of here
drug
lead_sponsor
company
collaborator
company
indication
investigator
person